10x Genomics reports Q4 EPS (40c), consensus (11c)

Reports Q4 revenue $165.0M, consensus $164.98M. “In 2024, we launched major new products across all three of our platforms and we made changes to our commercial organization and go-to-market strategy,” said CEO Serge Saxonov. “As we kick off 2025, our goal is to take advantage of these changes and deliver consistent execution. Despite the current uncertainty within U.S. academic research, we continue to have strong conviction in the large opportunity ahead.”